AKUMS

Akums Drugs and Pharmaceuticals News

₹824.90+1.26%
Market cap
₹12,629 crore
P/E
43.3
P/B
3.81
ROE
8.0%
Dividend yield
0.36%

The latest update on Akums Drugs and Pharmaceuticals is "AKUMS Reports Quarterly Financial Results & Operating Metrics Update" (BSE Corporate Announcement), published 7 October 2026. This page lists 4 recent headlines and exchange announcements, 2 of them filed on BSE.

Latest Akums Drugs and Pharmaceuticals news and announcements

  1. AKUMS Reports Quarterly Financial Results & Operating Metrics UpdateResults BSE Corporate Announcement · 7 Oct 2026
  2. Market Wrap: AKUMS Shares Trade Higher Following Positive Sector SentimentNews Economic Times · 6 Oct 2026
  3. AKUMS Board Approves Strategic Growth Initiatives & Governance FilingsExchange filing BSE Filings · 5 Oct 2026
  4. Analyst Commentary: Institutional Investors Review AKUMS Long-Term OutlookNews Financial Express · 3 Oct 2026

Source: Publisher headlines and announcements filed on BSE, linked to their original sources. Data as of 7 October 2026. How this data is compiled.

Akums Drugs and Pharmaceuticals news & announcements — frequently asked questions

What is the latest news on Akums Drugs and Pharmaceuticals?

The most recent item is "AKUMS Reports Quarterly Financial Results & Operating Metrics Update" from BSE Corporate Announcement on 7 October 2026. The full list above links to each original source.

Where do these Akums Drugs and Pharmaceuticals headlines come from?

Headlines link to the original publisher, and exchange announcements link to the filing on BSE. ATS lists them by date and does not rewrite or summarise them.

Same Data For Peers

Trade Akums Drugs and Pharmaceuticals With ATS

Track AKUMS live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.